Articles

Find an Article

Filter articles

Applied Filters

Showing 251 to 260 of 277 results

Quality control: biotech at the EPO

EU28-06-2013

The European Patent Office grants approximately 6,000 biotechnology patents per year. LSIPR spoke to Victor Kaas, director of biotechnology at the office, about how it faces the unique challenges of the industry.

Myriad: picking up the pieces

US28-06-2013Janis Fraser

The US Supreme Court in a landmark decision held that a DNA molecule is potentially eligible for patenting in the US if its sequence does not occur in nature, but is not patent-eligible if its sequence is identical to a naturally occurring DNA sequence.

A new approach to cancer target screening

Norway31-05-2013

BerGenBio’s ‘ask the cell’ technology could potentially change cancer treatment as we know it. With an expanding patent portfolio and library of trade secrets behind it, what challenges does the startup biotech company face in bringing its first drugs to market?

Obviousness of DNA fragments in the post-Kubin era

US30-04-2013James Monroe and Lawrence Ilag

James Monroe and Lawrence Ilag of Finnegan, Henderson, Farabow, Garrett & Dunner LLP analyse the impact of the US Court of Appeals for the Federal Circuit’s decision In re Kubin.

A global approach: Novo Nordisk's IP strategy

EU30-04-2013

While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.

Russia v Eurasia: national and regional differences in patentability

Belarus, Kazakhstan, Russia01-04-2013Maria Nilova and Elena Tsvetkova

There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain.

Considerations for biopharma under a first-inventor-to-file regime

01-04-2013Kenley Hoover

The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.

Biotech threats in the SPC system

EU01-04-2013Jaap Mannaerts

In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.

Post-grant patent challenges in Europe and the US: harmony at last?

EU, US01-04-2013Jane Wainwright and Daniel Young

Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.

Who's first? New rules on filing patents

US01-04-2013MaryAnne Armstrong

On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.

Showing 251 to 260 of 277 results

LSIPR